ASLAN004-003: A randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe atopic dermatitis.

Clinical trial for adults (age > 18) with at least a 6-month history of atopic dermatitis. In terms of severity, the trial requires a BSA involvement of >10% (and a minimum EASI score of 16). A subset of patients with prior dupixent exposure will be permitted to enter the study.

Study length: 16 weeks. NCT05158023

BSA is determined by measuring the number of handprints of involvement present. A handprint includes the palm and the fingers as shown in the image. 1-handprint is approximately equivalent to 1% of body surface area. In other words, if a study requires 10% – this will equate to 10-handprints.